Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

By Bissler JJ, Kingswood JC, Radzikowska E et al.

Double-blind, placebo-controlled, multicentre, registered NCT00790400